NMP22

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

NMP22 is a tumor marker for bladder cancer. NMP22 is the abbreviated form of Nuclear Matrix Protein No.22 [1][2][3] It reflects the mitotic activity of cells.
It has been developed as a FDA and CE approved bladder cancer detection marker commercialized under the name of NMP22 bladercheck®. Results can be obtained within 30 minutes. This test is proposed for screening, diagnosis and surveillance of bladder cancer in conjunction with standard diagnostic procedures. Nonetheless there are no recommendation for its systematic use in clinical practice based on clinical guidelines either from the US (American Urological Association guidelines) or in Europe (European Association of Urology guidelines) since there are no level 1 evidence showing that the use of this test would have a significant impact on bladder cancer outcomes.

References

  1. Lua error in package.lua at line 80: module 'strict' not found.
  2. Lua error in package.lua at line 80: module 'strict' not found.
  3. Lua error in package.lua at line 80: module 'strict' not found.

<templatestyles src="Asbox/styles.css"></templatestyles>